Pfizer’s High-Stakes Bid for Weight-Loss Drug Maker Intensifies
Published on 11/06/2025 at 15:14 | Redaktion boerse-global.de
The pharmaceutical industry is witnessing an intense bidding war as Pfizer competes against Danish rival Novo Nordisk for control of Metsera, a biotechnology firm specializing in GLP-1 medications for weight management. This multi-billion dollar contest represents a strategic pivot for Pfizer as it seeks to strengthen its position in the rapidly expanding obesity treatment market.
Pfizer’s ambitious takeover move comes immediately following a positive financial disclosure. On Tuesday, the company released quarterly results that surpassed market expectations and raised its full-year guidance, demonstrating underlying business resilience despite declining COVID-related revenue.
Key financial highlights include:
* Adjusted earnings per share of $0.87, substantially exceeding forecasts
* Operational growth of Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
